- Home
- NTZ vs IMMX Comparison
NTZ vs IMMX Comparison
Compare NTZ & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTZ
- IMMX
- Stock Information
- Founded
- NTZ 1959
- IMMX 2014
- Country
- NTZ Italy
- IMMX United States
- Employees
- NTZ N/A
- IMMX N/A
- Industry
- NTZ Home Furnishings
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- NTZ Consumer Discretionary
- IMMX Health Care
- Exchange
- NTZ Nasdaq
- IMMX Nasdaq
- Market Cap
- NTZ 51.8M
- IMMX 61.1M
- IPO Year
- NTZ 1993
- IMMX 2021
- Fundamental
- Price
- NTZ $4.91
- IMMX $2.04
- Analyst Decision
- NTZ
- IMMX Strong Buy
- Analyst Count
- NTZ 0
- IMMX 1
- Target Price
- NTZ N/A
- IMMX $7.00
- AVG Volume (30 Days)
- NTZ 15.4K
- IMMX 135.6K
- Earning Date
- NTZ 12-12-2024
- IMMX 11-12-2024
- Dividend Yield
- NTZ N/A
- IMMX N/A
- EPS Growth
- NTZ N/A
- IMMX N/A
- EPS
- NTZ N/A
- IMMX N/A
- Revenue
- NTZ $365,846,531.00
- IMMX N/A
- Revenue This Year
- NTZ N/A
- IMMX N/A
- Revenue Next Year
- NTZ N/A
- IMMX $200.00
- P/E Ratio
- NTZ N/A
- IMMX N/A
- Revenue Growth
- NTZ N/A
- IMMX N/A
- 52 Week Low
- NTZ $3.80
- IMMX $1.26
- 52 Week High
- NTZ $6.50
- IMMX $5.73
- Technical
- Relative Strength Index (RSI)
- NTZ 56.77
- IMMX 46.03
- Support Level
- NTZ $4.63
- IMMX $2.15
- Resistance Level
- NTZ $4.93
- IMMX $2.49
- Average True Range (ATR)
- NTZ 0.33
- IMMX 0.19
- MACD
- NTZ 0.02
- IMMX -0.04
- Stochastic Oscillator
- NTZ 92.18
- IMMX 23.70
About NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio including sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of revenue from the United States of America and also has an international presence in Italy, Spain, UK and Other countries.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.